The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies
Author
Abstract
Suggested Citation
DOI: 10.1007/s40273-013-0041-x
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Jena, Anupam B. & Philipson, Tomas J., 2008. "Cost-effectiveness analysis and innovation," Journal of Health Economics, Elsevier, vol. 27(5), pages 1224-1236, September.
- Giaccotto, Carmelo & Santerre, Rexford E & Vernon, John A, 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 48(1), pages 195-214, April.
- Thomas A. Abbott & John A. Vernon, 2005. "The Cost of US Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions," NBER Working Papers 11114, National Bureau of Economic Research, Inc.
- Frank A. Sloan & Hirschel Kasper (ed.), 2008. "Incentives and Choice in Health Care," MIT Press Books, The MIT Press, edition 1, volume 1, number 0262693658, April.
- Bardey, D. & Bommier, A. & Jullien, B., 2010.
"Retail price regulation and innovation: Reference pricing in the pharmaceutical industry,"
Journal of Health Economics, Elsevier, vol. 29(2), pages 303-316, March.
- Bardey, David & Bommier, Antoine & Jullien, Bruno, 2009. "Retail Price Regulation and Innovation: Reference Pricing in the Pharmaceutical Industry," TSE Working Papers 09-026, Toulouse School of Economics (TSE).
- Bardey, David & Bommier, Antoine & Jullien, Bruno, 2009. "Retail Price Regulation and Innovation: Reference Pricing in the Pharmaceutical Industry," IDEI Working Papers 432, Institut d'Économie Industrielle (IDEI), Toulouse.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Rodrigo Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2014. "Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 439-445, May.
- Alan Haycox, 2013. "How Much Should the NHS Pay for a QALY?," PharmacoEconomics, Springer, vol. 31(5), pages 357-359, May.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Refoios Camejo, Rodrigo & McGrath, Clare & Herings, Ron, 2011. "A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness," Health Policy, Elsevier, vol. 100(1), pages 18-24, April.
- Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
- Frank R. Lichtenberg, 2007.
"Importation And Innovation,"
Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 16(6), pages 403-417.
- Frank R. Lichtenberg, 2006. "Importation and Innovation," NBER Working Papers 12539, National Bureau of Economic Research, Inc.
- Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015.
"Market size and pharmaceutical innovation,"
RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," TSE Working Papers 11-232, Toulouse School of Economics (TSE), revised Mar 2014.
- Seabright, Paul & Scott Morton, Fiona & Dubois, Pierre & de Mouzon, Olivier, 2011. "Market Size and Pharmaceutical Innovation," CEPR Discussion Papers 8367, C.E.P.R. Discussion Papers.
- Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 90(C).
- Paolo Pertile & Simona Gamba & Martin Forster, 2018. "Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence," Discussion Papers 18/04, Department of Economics, University of York.
- Rodrigo Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2014. "Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 439-445, May.
- Basu, Anirban & Jena, Anupam B. & Philipson, Tomas J., 2011.
"The impact of comparative effectiveness research on health and health care spending,"
Journal of Health Economics, Elsevier, vol. 30(4), pages 695-706, July.
- Anirban Basu & Tomas J. Philipson, 2010. "The Impact of Comparative Effectiveness Research on Health and Health Care Spending," NBER Working Papers 15633, National Bureau of Economic Research, Inc.
- Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Bardey, David & Cremer, Helmuth & Lozachmeur, Jean-Marie, 2016.
"The design of insurance coverage for medical products under imperfect competition,"
Journal of Public Economics, Elsevier, vol. 137(C), pages 28-37.
- Bardey, David & Cremer, Helmuth & Lozachmeur, Jean-Marie, 2015. "The Design of Insurance Coverage for Medical Products under Imperfect Competition," IZA Discussion Papers 8815, Institute of Labor Economics (IZA).
- David Bardey & Helmuth Cremer & Jean-Marie Lozachmeur, 2015. "The Design of Insurance Coverage for Medical Products under Imperfect Competition," CESifo Working Paper Series 5235, CESifo.
- Bardey, David & Cremer, Helmuth & Lozachmeur, Jean-Marie, 2015. "The design of insurance coverage for medical products under imperfect competition," TSE Working Papers 15-553, Toulouse School of Economics (TSE).
- David Bardey & Helmuth Cremer & Jean-Marie Lozachmeur, 2015. "The design of insurance coverage for medical products under imperfect competition," Documentos CEDE 12564, Universidad de los Andes, Facultad de Economía, CEDE.
- Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011.
"Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment,"
Journal of Public Economics, Elsevier, vol. 95(7), pages 624-638.
- Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7-8), pages 624-638, August.
- Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2010. "Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment," CESifo Working Paper Series 3258, CESifo.
- Lee, Daeyong, 2018. "Impact of the excise tax on firm R&D and performance in the medical device industry: Evidence from the Affordable Care Act," Research Policy, Elsevier, vol. 47(5), pages 854-871.
- Brekke, Kurt R. & Holmås, Tor Helge & Straume, Odd Rune, 2015.
"Price regulation and parallel imports of pharmaceuticals,"
Journal of Public Economics, Elsevier, vol. 129(C), pages 92-105.
- Brekke, Kurt R. & Holmås, Tor Helge & Straume, Odd Rune, 2014. "Price Regulation and Parallel Imports of Pharmaceuticals," Discussion Paper Series in Economics 1/2014, Norwegian School of Economics, Department of Economics.
- Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2014. "Price Regulation and Parallel Imports of Pharmaceuticals," NIPE Working Papers 01/2014, NIPE - Universidade do Minho.
- Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2015. "Price Regulation and Parallel Imports of Pharmaceuticals," CESifo Working Paper Series 5469, CESifo.
- Casson, Mark & Porter, Lynda & Wadeson, Nigel, 2016. "Internalization theory: An unfinished agenda," International Business Review, Elsevier, vol. 25(6), pages 1223-1234.
- Jim Attridge, 2007. "Innovation Models In The Biopharmaceutical Sector," International Journal of Innovation Management (ijim), World Scientific Publishing Co. Pte. Ltd., vol. 11(02), pages 215-243.
- Francesca Barigozzi & Izabela Jelovac, 2020.
"Research funding and price negotiation for new drugs,"
Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 83-96, October.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02409758, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2020. "Research funding and price negotiation for new drugs," Post-Print halshs-02910863, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Working Papers 1901, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02409768, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02148454, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Working Papers halshs-01987643, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02148462, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02409743, HAL.
- Gilad Sorek, 2014. "Price Controls For Medical Innovations In A Life Cycle Perspective," Health Economics, John Wiley & Sons, Ltd., vol. 23(1), pages 108-116, January.
- Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
- Rosella Levaggi & Paolo Pertile, 2020. "Which valued‐based price when patients are heterogeneous?," Health Economics, John Wiley & Sons, Ltd., vol. 29(8), pages 923-935, August.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:31:y:2013:i:5:p:445-454. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.